Snipr Biome takes aim at antibiotic resistant bacteria in phase I trial
Danish biotech company Snipr Biome, which is developing a new type of antibiotics using the gene-editing tool CRISPR, is sending its first candidate to clinic. ”It’s a huge day for us,” says CEO Christian Grøndahl.
by andreas lønstrup, translated by daniel pedersen
Danish biotech firm Snipr Biome announced on Wednesday that the first dose had been administered in a phase I trial with a potentially preventive treatment against E.coli infections in the gut.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Snipr Biome brings first candidate to human trial
For subscribers
FDA fast-tracks Snipr Biome's primary candidate
For subscribers
Snipr Biome chose clinical debut in CRISPR-ready USA
For subscribers
